After leading a study that patients with acute myeloid leukemia who receive induction chemotherapy are quite distressed, Tom LeBlanc, hematologic malignancy specialist at Duke Cancer Institute, decided more palliative care should be offered alongside treatment for the disease.
Thanks! Share it with your friends!
After leading a study that patients with acute myeloid leukemia who receive induction chemotherapy are quite distressed, Tom LeBlanc, hematologic malignancy specialist at Duke Cancer Institute, decided more palliative care should be offered alongside treatment for the disease.
){kind=link}
Comments